Skip to main content
. 2021 Nov 1;22(1):e13–e27. doi: 10.1016/S1473-3099(21)00400-X

Table 2.

Preclinical and clinical evidence for candidate monoclonal antibodies against henipaviruses

Evidence available Current development stage Target Developer
mAb 102·4 Human (phase 1 trial), ferrets, and African green monkeys47, 48, 49, 50 Phase 1 HeV or NiV G glycoprotein Henry M Jackson Foundation for the Advancement of Military Medicine (Bethesda, MD, USA)
mAb 5B3, mAb h5B3·1 Mice and ferrets51, 52 Preclinical HeV or NiV pre-fusion F glycoprotein University of Washington (Seattle, WA, USA) and Uniformed Services University (Bethesda, MD, USA)
mAb HENV-26, mAb HENV-32 Ferrets53 Preclinical HeV or NiV G glycoprotein (receptor-binding protein) Vanderbilt Vaccine Center (Nashville, TN, USA)
Anti-G mAb, anti-F mAb Hamsters54 Preclinical NiV G and F glycoprotein INSERM (Paris, France), Université Claude Bernard Lyon 1 (Lyon, France), and Institut Pasteur (Paris, France)

HeV=Hendra virus. mAb=monocolonal antibody. NiV=Nipah virus.